Used in the development of targeted immunotherapies for T-cell malignancies, this antibody serves as a critical tool in chimeric antigen receptor (CAR) T-cell therapies. It enables selective targeting of CD7-expressing cancer cells, such as those in T-cell acute lymphoblastic leukemia (T-ALL) and other aggressive T-cell lymphomas. Due to its high specificity, it supports the engineering of CAR-T cells that minimize off-target effects while enhancing tumor cell clearance. Additionally, it is employed in diagnostic assays to detect CD7 expression in patient samples, aiding in disease classification and treatment planning. Its role in blocking CD7-mediated signaling also contributes to research on immune regulation and T-cell activation pathways.